# Harnessing natural compounds and nanotechnology for miRNA-based osteosarcoma therapy

**Authors:** Abdullah AlAqel, Gharieb S. El-Sayyad, Shaza H. Aly, Ahmed E. Elesawy, Osama A. Mohammed, Hend H. Mohamed, Walaa A. El-Dakroury, Maha Abdelsalam, Ahmed S. Doghish

PMC · DOI: 10.1039/d5ra06010a · RSC Advances · 2026-02-09

## TL;DR

This paper explores combining natural compounds and nanotechnology to improve miRNA-based treatments for osteosarcoma, a challenging bone cancer.

## Contribution

It introduces a novel approach integrating natural bioactive molecules with nanocarriers to enhance miRNA delivery and therapeutic efficacy.

## Key findings

- Natural compounds like resveratrol and quercetin modulate miRNA expression to inhibit osteosarcoma progression.
- Nanotechnology enables targeted and sustained delivery of miRNA modulators, reducing toxicity.
- Combining natural agents with nanomedicine offers synergistic anti-cancer effects with fewer side effects.

## Abstract

Osteosarcoma remains one of the most challenging malignancies due to its aggressive nature, metastatic potential, and resistance to conventional therapies. Recent advances have underscored the pivotal role of microRNAs (miRNAs) in the regulation of key oncogenic and tumor suppressor pathways involved in osteosarcoma progression, including PI3K/AKT, Wnt/β-catenin, and TGF-β signaling. The modulation of miRNAs offers a promising therapeutic avenue, but effective delivery systems are essential to realize their full potential. Natural compounds derived from plants, such as flavonoids, resveratrol, quercetin, and epigallocatechin-3-gallate, have demonstrated notable capacity to modulate miRNA expression, inducing apoptosis, inhibiting proliferation, and reducing metastasis with fewer adverse effects compared to traditional chemotherapy. These bioactive molecules possess intrinsic anti-inflammatory, antioxidant, and osteogenic properties, which, when combined with miRNA regulation, can synergistically impede osteosarcoma progression. Nanotechnology-based delivery systems, including multilayered nanoparticles, magnetic nanostructures, and biodegradable nanocarriers, have emerged as effective platforms to overcome these obstacles. These nanocarriers can be engineered for targeted, controlled, and sustained release of therapeutic agents, enhancing accumulation at tumor sites while minimizing systemic toxicity. Additionally, functionalization with targeting ligands such as folic acid or antibodies further improves specificity towards osteosarcoma cells. This review emphasizes the potential of combining natural compounds with nanotechnology to develop innovative, targeted, and effective therapies for osteosarcoma. It highlights the opportunities for future research to optimize delivery systems, elucidate mechanisms of action, and establish clinical applicability. By harnessing the biological benefits of natural agents and the precision of nanomedicine, these approaches hold significant promise for improving therapeutic outcomes and reducing adverse effects in osteosarcoma treatment.

This review emphasizes the potential of combining natural compounds with nanotechnology to develop innovative, targeted, and effective therapies for osteosarcoma.

## Linked entities

- **Chemicals:** resveratrol (PubChem CID 5056), quercetin (PubChem CID 5280343), epigallocatechin-3-gallate (PubChem CID 65064)
- **Diseases:** osteosarcoma (MONDO:0002623)

## Full-text entities

- **Genes:** CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** metastasis (MESH:D009362), inflammatory (MESH:D007249), Osteosarcoma (MESH:D012516), toxicity (MESH:D064420), malignancies (MESH:D009369)
- **Chemicals:** quercetin (MESH:D011794), folic acid (MESH:D005492), flavonoids (MESH:D005419), resveratrol (MESH:D000077185), epigallocatechin-3-gallate (MESH:C045651)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12885115/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12885115/full.md

## References

87 references — full list in the complete paper: https://tomesphere.com/paper/PMC12885115/full.md

---
Source: https://tomesphere.com/paper/PMC12885115